ADARx Pharmaceuticals IPO: $17 pricing on 2026-09-24
ADARx Pharmaceuticals priced 26,250,000 shares at $17 in its dated 2026-09-24 announcement, with approximately $446.3 million base gross proceeds.
Dated offering terms — 2026-09-24
ADARx Pharmaceuticals announced a price of $17 for 26,250,000 shares, representing about $446.3 million before fees. Its announcement expected Nasdaq Global Select Market trading under ADRX on 25 September 2026. Closing was expected on 28 September 2026, subject to conditions.
ADARx develops siRNA medicines. Its release separately describes a concurrent AbbVie private placement and about $535.2 million combined gross proceeds. The public base offering and that private investment are different components of the financing.
What the financing changes
The distinction matters when comparing deal sizes: adding a strategic placement to the public offering can overstate the amount sold to public investors. The combined financing may support a wider development program, but clinical execution remains the test. Useful follow-up reporting would connect spending with individual programs and expected study milestones. Strategic participation also needs to be read alongside the contractual relationship rather than treated as independent proof of a medicine's eventual approval.
The trading timetable above records the issuer's expectations at pricing; it is not a live market-price quotation.